Company profile: Century Therapeutics
1.1 - Company Overview
Company description
- Provider of iPSC-derived allogeneic NK and T cell therapies for cancer and autoimmune diseases, including CNTY-101 targeting CD19-positive B-cell lymphomas (Phase 1 ELiPSE-1). Offers CRISPR-MAD7 mediated HDR gene editing, Allo-Evasion technology for immune evasion and repeat dosing, CAR and protein engineering, and common engineered iPSC progenitors to accelerate development.
Products and services
- IPSC-derived NK and T cell therapies: Allogeneic, iPSC-based products built for hematological and solid cancers and autoimmune diseases, leveraging induced pluripotent stem cells to generate NK and T cell assemblies
- Allo-Evasion™ technology: Custom-engineered system that enables cell therapy products to elude host immune surveillance, facilitating repeated dosing by reducing detection by the recipient immune system
- CNTY-101: Clinical-stage cell therapy engineered to target CD19-positive B-cell lymphomas, currently under evaluation in the Phase 1 ELiPSE-1 clinical trial
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Century Therapeutics
Aadi Bioscience
HQ: United States
Website
- Description: Provider of a potential mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aadi Bioscience company profile →
Allorion Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule therapeutics for cancer and autoimmune diseases, including an EGFR L858R allosteric inhibitor program to enhance existing treatments and prevent resistance; ARTS-021, an oral CDK2 inhibitor in Phase I/II for advanced/metastatic solid tumors; ARTS-011, a selective TYK2 inhibitor in early development; and high-throughput phenotypic screening to identify Werner Helicase inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allorion Therapeutics company profile →
Medigene
HQ: Germany
Website
- Description: Provider of biotechnology solutions for cancer treatment, offering an end-to-end platform for developing TCR-guided therapies—including TCR-T, TCR-T cell engagers, and TCR-natural killer cell therapies—focused on specificity, sensitivity, and safety. Pipeline includes MDG1015 (NY-ESO-1/LAGE-1a, PD1-41BB) and MDG2011 (KRAS G12V, PD1-41BB) for solid tumors, plus 3S TCR technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medigene company profile →
Nuvectis Pharma
HQ: United States
Website
- Description: Provider of novel targeted cancer therapeutics, including NXP800, an oral small molecule activator of GCN2 in clinical trials for platinum-resistant, ARID1a-mutated ovarian cancer and cholangiocarcinoma, and NXP900, an oral small molecule inhibitor of SRC family kinases (SFK), including SRC and YES1, currently in a Phase 1 dose escalation clinical trial.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvectis Pharma company profile →
Synta Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule therapeutics to treat cancer and chronic inflammatory diseases, focused on the development and commercialization of these drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synta Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Century Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Century Therapeutics
2.2 - Growth funds investing in similar companies to Century Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Century Therapeutics
4.2 - Public trading comparable groups for Century Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →